We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GoodRx Holdings, Inc. (GDRX) Surges 13.3%: Is This an Indication of Further Gains?
Read MoreHide Full Article
GoodRx Holdings, Inc. (GDRX - Free Report) shares rallied 13.3% in the last trading session to close at $6.47. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.2% loss over the past four weeks.
GoodRx scored a strong price increase, on investors’ optimism driven by the company’s announcement of preliminary financial results for the fourth quarter and fiscal year ended Dec 31, 2023. The company’s fourth quarter revenues are expected to be within $195 million-$197 million, higher than the Zacks Consensus Estimate of $189.6 million. For the full year 2023, revenues are anticipated to be between $749 million-$751 million, while the Zacks Consensus Estimate remains at $748.4 million.
This company is expected to post quarterly earnings of $0.07 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $189.58 million, up 3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For GoodRx Holdings, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on GDRX going forward to see if this recent jump can turn into more strength down the road.
GoodRx Holdings, Inc. is part of the Zacks Medical Services industry. NovoCure (NVCR - Free Report) , another stock in the same industry, closed the last trading session 4.9% lower at $14.02. NVCR has returned 19.5% in the past month.
For NovoCure, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.53. This represents a change of -47.2% from what the company reported a year ago. NovoCure currently has a Zacks Rank of #2 (Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GoodRx Holdings, Inc. (GDRX) Surges 13.3%: Is This an Indication of Further Gains?
GoodRx Holdings, Inc. (GDRX - Free Report) shares rallied 13.3% in the last trading session to close at $6.47. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.2% loss over the past four weeks.
GoodRx scored a strong price increase, on investors’ optimism driven by the company’s announcement of preliminary financial results for the fourth quarter and fiscal year ended Dec 31, 2023. The company’s fourth quarter revenues are expected to be within $195 million-$197 million, higher than the Zacks Consensus Estimate of $189.6 million. For the full year 2023, revenues are anticipated to be between $749 million-$751 million, while the Zacks Consensus Estimate remains at $748.4 million.
This company is expected to post quarterly earnings of $0.07 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $189.58 million, up 3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For GoodRx Holdings, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on GDRX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
GoodRx Holdings, Inc. is part of the Zacks Medical Services industry. NovoCure (NVCR - Free Report) , another stock in the same industry, closed the last trading session 4.9% lower at $14.02. NVCR has returned 19.5% in the past month.
For NovoCure, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.53. This represents a change of -47.2% from what the company reported a year ago. NovoCure currently has a Zacks Rank of #2 (Buy).